14th Health and Safety Conference: Multinational Pharmaceutical Companies Lead Sustainable Development

Business Agency, May 3 , from the recent china Foreign Investment Enterprise AssociationPharmaceuticalResearch and Development Industry Committee (RDPAC) 14th Environmental Health and Safety (EHS) panel meeting, research and development of pharmaceuticalenterpriseshope to further deepen the promotion of sustainable development strategy in China"The main elements of sustainable development are economic, ecological and social sustainable development, with economic sustainability as the foundation, ecological sustainability as the condition and social sustainability being the end of the year," said Ong Fuyi, special adviser to the EHS Group, whichto attend the conference for seven consecutive yearsResearch and development pharmaceutical enterprises in the sustainable development of the efforts throughout all three aspects, and ultimately implemented to "people-oriented" onIn general, the protection of the ecological environment and the protection of occupationalhealthare the two major priorities"
economically, many research and development pharmaceutical companies have fully integrated the concept of sustainable development into their development strategies, evaluated and adapted the sustainability plans being implemented, and actively tapped the potential to implement sustainability strategies at all levels of their operations."
"In fact, in terms of sustainability, we also pursue a full chain of monitoring, not only to abide by the principles of sustainable development, but also to require third parties to do so." It's not about being good, it's about being good"We require all third-party contractors to sign our Code of Business Conduct and receive ethics and compliance training," Abbott Said"Johnson and Johnson has also explicitly stated in its Healthy Future 2015 plan that it will strengthen its cooperation with third-party suppliers that support sustainability in addition, in the area of ecological sustainability, research and development of pharmaceutical companies can also be said to be a success In response to the situation in China, research and development pharmaceutical companies have also focused their environmental efforts on climate change, water use and product management The Abbott Shanghai plant has reduced water use by 31% since 2006; 23,287 kilowatts of electricity are replaced by new landscape complementary systems each year "Mersadong is at the forefront of the industry in recycling insulation vaccine transport containers and reducing landfills We are gradually moving away from PVC plastics and replacing them with bags made of recyclable materials, reducing waste by 400,000 pounds per year Ding Hanzhang, factory manager of Hangzhou Mercadong Pharmaceutical Co., Ltd., said
"Ultimately, whether it's economically sustainable or ecologically sustainable, it should ultimately be implemented in human health The essence of development is "people-oriented" Mr Ong said For the public, research and development companies continue to introduce innovative products and services to help people meet the challenges of diseases, while also leveraging their technical and intellectual strengths in the field of health to help the public improve their health For example, the China Neonatal Resuscitation Program (NRP), a joint initiative of Johnson and Johnson, the Chinese Ministry of Health and the American Academy of Pediatrics, is dedicated to addressing neonatal asphyxia Since its launch in the second half of 2004, the project has saved an average of 20,000 newborns a year Pfizer, Novo nor Nordisk have launched programs to help employees quit smoking "This kind of project to help employees live a healthy life is a lot of research and development pharmaceutical companies, so that employees are happy to work, health and well-being back home, rather than falling to work, which is what research and development pharmaceutical companies like," said one employee who works for an RDPAC member company
"Research and development pharmaceutical companies have accumulated a lot of experience in sustainable development, many projects for China have a good reference for other enterprises "While at the moment, companies have a high cost of pursuing sustainable development strategies, we, as research and development pharmaceutical companies, should take on more responsibility in this area and become a leader in sustainable development because we believe that this is a win-win strategy," said Zhuo Yongqing, CEO of RDPAC (Author: Du Wei)